May 17, 2020

India is looking to decline China’s acquisition of one of its leading pharma companies

healthcare services
healthcare services
Catherine Sturman
2 min
India is looking to disregard the purchase of Gland Pharma Ltd by Chinese pharmaceutical company Shanghai Fosun Pharmaceutical Group. Although it would...

India is looking to disregard the purchase of Gland Pharma Ltd by Chinese pharmaceutical company Shanghai Fosun Pharmaceutical Group. Although it would become the largest financial acquisition India would have seen by a Chinese company to date, reaching $1.3 billion the potential acquisition has caused increased concerns.

Gland Pharma was established back in 1978 in Hyderabad to manufacture and market Heparin for the domestic market. However, it has now become a key global player in the pharma market, with a presence in five continents. With its manufacturing facilities are globally approved, the company wa also the first liquid injectable facility in India to become approved by the US Food and Drug Administration, entering the country successfully in 2007.

Although China has gone through the necessary processes to obtain the approval of the Competition Commission of India (CCI) and India’s Foreign Investment Promotion Board, these concerns have now led The Cabinet Committee on Economic Affairs seeking to block the deal, according to recent reports.

The company’s complex purchase of an 86% of Gland Pharma is a result of the simmering tensions between the two countries, which has been a long-standing issue since the early 1960s.

The news has led to a fall in Fosun Pharma’s shares by 1.8%, and will heavily thwart the company’s plans to undertake the manufacturing of pharmaceutical products, which could be distributed within the US.

Abhijit Joshi, a mergers and acquisitions lawyer and managing partner at Veritas Legal in Mumbai, informed The Washington Post: “This is almost like a sanction. Rejecting a deal like this is almost like sending a signal to say, ‘no Chinese business,’ which means there could be a retaliatory action, trade wise, by China.”

Share article

Jun 22, 2021

Bachem turns 50 - a timeline

3 min
As Bachem turns 50, we take a look at the company's history

Bachem, a supplier to pharmaceutical and biotechnology companies worldwide, is celebrating its 50th anniversary this month. We take a look at the Swiss company's history.  

1971 - beginnings

Bachem is founded by entrepreneur Peter Grogg in Liestal, a small town near Basel in Switzerland. Grogg started the firm with just two employees, and with a focus on peptide synthesis - peptides are composed of amino acids that have a variety of functions treating health conditions such as cancer and diabetes. 

1977 - 1981 - early growth

Bachem moves its headquarters to the Swiss town of Bubendorf, with eight employees. In 1978 the company produces peptides for use in medicines for the first time. In 1981 production capacity triples and the workforce grows to 150. 

 1987 - 1996 - worldwide expansion

The company expands into the US with Bachem Bioscience, Inc. in Philadelphia. To strengthen its presence in Europe, Bachem opens sales and marketing centres in Germany in 1988. 

Further sales centres open in France in 1993. By 1995 the company employs 190 people. In 1996 it acquires the second largest manufacturer of peptides in the world and forms Bachem California with a site in Torrance. 

 1998 - 2003 - Bachem goes public

Bachem company goes public and lists shares on the Swiss Stock Exchange. Further acquisitions include Peninsula Laboratories, Inc, based in California, and  Sochinaz SA, a Swiss-based manufacturer of active pharmaceutical ingredients.  By 2001, the company has 500 employees and sales reach 141 million CHF.

In 2003 the organisation is given a new legal holding structure to support its continued growth, which remains in place to this day. 

2007 - 2013 - acquisitions

Bachem acquires a brand by Merck Biosciences for ready-to-use clinical trial materials and related services. 

In 2013, together with GlyTech, Inc. Bachem announces the development of a new amino acid that can help to treat multiple sclerosis, with a world market of more than $4 billion. 

In 2015 it acquires the American Peptide Company (APC), which becomes integrated into Bachem Americas. 

2016 - 2019 - a global leader

In 2016 the group opens a new building dedicated to R&D projects and small series production in Bubendorf. With a total of 1,022 employees, the workforce exceeds the 1,000 mark for the first time in the company’s history. Sales are over the 200 million mark for the first time at 236.5 million CHF.
Bachem expands into Asia with the establishment of a new company in Tokyo called Bachem Japan K.K. 

By 2019 Bachem has a growing oligonucleotide portfolio - these are DNA molecules used in genetic testing, research, and forensics. It is hoped this will become a significant product range in the future. 

2020 - COVID-19

Despite the COVID-19 pandemic, Bachem secures its supply of active ingredients, and even increases it in critical areas. Sales exceed the 400 million Swiss franc mark for the first time, and  272 new employees are hired.  

2021 - a milestone anniversary

Bachem celebrates its 50th anniversary and position as a global leader in the manufacture of peptides. While it  remains headquartered in Bubendorf, the company employs 1,500 people at six locations worldwide. In the next five years there are  plans to continue expanding. 

Commemorating the company's anniversary, Kuno Sommer, Chairman of the Board of Directors, said: "Bachem's exceptional success story from a small laboratory to a global market leader is closely linked to Peter Grogg's values, and has been shaped by innovation, consistent quality and cost awareness, as well as by entrepreneurial vision."

Share article